Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Chinese Medical JournalOpen Access

Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

XGXuanjun GuoYLYixin LiMWMengying Wang

Discussion

Loading...

Member takes

Overview

Systematic review and network meta-analysis assess treatment efficacy and safety for metastatic castration-resistant prostate cancer, highlighting key outcomes.

Key Points

  • PARPi doublet with ARSI showed improvements in radiographic progression-free survival and overall survival in mCRPC patients with HRR gene alterations.
  • In 35 randomized controlled trials involving 24,400 patients, combination therapies demonstrated no significant difference in OS compared to docetaxel.
  • The systematic review included multiple databases and employed subgroup analysis, meta-regression, and sensitivity analyses to explore treatment efficacy.
  • Findings suggest the need for caution regarding safety profiles, particularly for the PARPi doublet with ARSI in treating mCRPC.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d647902efhttps://doi.org/10.1097/cm9.0000000000003709
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis2025
  2. 2PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.2025
  3. 3The efficacy and safety of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis based on randomized controlled trials2025
  4. 4A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer2025 · 1 citations
  5. 5Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study2025